

## Special Issue

# Treatment-Related Predictive and Prognostic Factors in Lung Cancer

### Message from the Guest Editors

Lung cancer is a major cause of cancer death worldwide. Surgery is a standard therapy for patients with early-stage lung cancer. Prognostic factors for early-stage lung cancer patients are important for clinicians to determine the postoperative follow-up and to choose patients who should receive the adjuvant chemotherapy. In addition, there have been dramatic pharmacotherapy developments for non-small-cell lung cancer patients; in addition to chemotherapy, molecular-targeted drugs, such as epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors, have been adopted in the clinic. Recently, immunotherapy targeting programmed cell death 1 or programmed death-ligand 1 has gathered great attention as a novel pharmacological treatment. It is important to discover the factors that can be used to select patients who will benefit from such treatments. In this Special Issue, we welcome reports on the treatment-related predictive and prognostic factors in lung cancer.

### Guest Editors

Dr. Shinkichi Takamori

Department of Thoracic Oncology, National Hospital Organization  
Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395,  
Japan

Dr. Kazuki Takada

Department of Thoracic Surgery, Kitakyushu Municipal Medical Center,  
2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, Fukuoka, Japan

### Deadline for manuscript submissions

closed (31 January 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/68049](https://mdpi.com/si/68049)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)